share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Kewalramani Reshma

SEC announcement ·  Feb 28 06:04
Summary by Futu AI
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.